Core Viewpoint - The approval of the "Monkey Zao Chutian San" by the National Medical Products Administration marks a significant milestone for the company, indicating the successful implementation of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bitian Tang (00897), rose by 11.36% to HKD 0.49, with a trading volume of HKD 2.5302 million [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey Zao Chutian San," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval represents the first product to be granted market access under the newly simplified registration policy for traditional Chinese medicine, highlighting the effectiveness of regulatory changes in the industry [1]

Core Viewpoint - The approval of the "Monkey's Paw Phlegm-Removing Powder" for mainland market entry marks a significant milestone for the company, reflecting the effectiveness of the simplified registration policy for traditional Chinese medicine in Hong Kong and Macau [1] Company Summary - The company's stock, Bit Yuan Tang (00897), rose over 11%, reaching a price of 0.49 HKD with a trading volume of 2.53 million HKD [1] - The company’s flagship products include the "An Gong Niu Huang Wan" series, the classic "Yang Yin Wan," and the "Monkey's Paw Phlegm-Removing Powder," which has been a sales champion for ten consecutive years [1] Industry Summary - The approval of the product is the first instance of a traditional Chinese medicine being granted entry into the mainland market under the new simplified registration policy, indicating a positive trend for the industry [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司) 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.0 ...

Group 1 - The core point of the article highlights that on September 16, Bitland (00897) transferred shares from BNP Paribas to Bank of Communications (Hong Kong), with a market value of HKD 300 million, accounting for 71.16% of the shares [1] - Bitland reported its financial results for the year ending March 31, 2025, showing revenue from continuing operations of approximately HKD 745 million, a year-on-year decrease of 4.9% [1] - The company achieved a profit attributable to equity holders of HKD 7.1 million, marking a turnaround from a loss in the previous year, with earnings per share of HKD 0.63 [1]

（原标题：位元堂(00897)股东将股票由法国巴黎银行转入交通银行(香港) 转仓市值3亿港元） 位元堂公布的截至2025年3月31日止年度业绩显示，公司持续经营业务收益约7.45亿港元，同比减少 4.9%；母公司拥有人应占溢利710万港元，同比扭亏为盈；每股盈利0.63港仙。 智通财经APP获悉，香港联交所最新资料显示，9月16日，位元堂(00897)股东将股票由法国巴黎银行转 入交通银行(香港)，转仓市值3亿港元，占比71.16%。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | 本月底法定/註冊股本總額： HKD 600,000,000 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責，對 其準確性或完整性亦不發表聲明，並明確表示，概不就因本公佈全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WAI YUEN TONG MEDICINE HOLDINGS LIMITED (位元堂藥業控股有限公司* ) (於百慕達註冊成立之有限公司) (股份代號: 897) 於二零二五年八月十九日舉行之 股東週年大會之投票結果 董事會欣然宣佈，所有載於股東週年大會通告內提呈之決議案已於二零二五年 八月十九日舉行之股東週年大會上，以投票方式獲股東正式通過。 茲提述 Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司* ) (「本公 司」) 日期為二零二五年七月二十五日之通函 (「該通函」)，其中載有日期為二零二五 年七月二十五日之通告(「股東週年大會通告」)以召開本公司於二零二五年八月十九 日舉行之股東週年大會(「股東週年大會」)。除另有說明者外，本公佈所用詞彙與該 通函所界定者具有相同涵義。 1 | 普通決議案 | (註) | 股份數目 | | | --- | ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00897 | 說明 | 位元堂 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 60,000,000,000 | HKD | | 0.01 HKD | | 600,000,000 | 本月底法定/註冊股本總額： HKD 600,000,000 FF301 致：香港交易及結算所有限公司 公 ...

According to authoritative market research reports, Wai Yuen Tong is widely recognized as the leading brand offering the best quality Chinese medicine among various brands in the sector. Contents 目錄 | CORPORATE INFORMATION | 公司資料 | 2 | | --- | --- | --- | | AWARDS | 獎項 | 5 | | CHAIRMAN'S STATEMENT | 主席報告 | 6 | | MANAGEMENT DISCUSSION AND ANALYSIS | 管理層討論及分析 | 10 | | BOARD OF DIRECTORS AND SENIOR MANAGEMENT | 董事會及高級管理層 | 21 | | CORPORATE GOVERNANCE REPORT | 企業管治報告 | 28 | | REPORT OF THE DIRECTORS | 董事會報告 | 5 ...

Core Viewpoint - Shankai Intelligent plans to change its controlling shareholder to Hubei Changjiang Aerospace Technology Investment Co., Ltd., with the actual controller becoming the State-owned Assets Supervision and Administration Commission of the People's Government of Xinzhou District, Wuhan [2][4]. Group 1: Shareholder Changes - The stock suspension for Shankai Intelligent began on July 10 and is set to resume trading on July 17, following a significant price increase, including a 20% surge on July 7 [4]. - The share transfer agreement indicates that several shareholders will transfer their shares to Changjiang Aerospace, resulting in Changjiang Aerospace holding 19.70% of Shankai Intelligent's shares at a price of 20.70 yuan per share, totaling 572 million yuan [7][9]. - The transfer price represents an 18.37% discount compared to the closing price of 25.36 yuan per share on July 9 [7]. Group 2: Financial Performance - Shankai Intelligent's recent financial performance has shown a decline, with net profits for 2024 and the first quarter of 2025 reported at 81.45 million yuan and 9.39 million yuan, respectively, reflecting year-on-year decreases of 12.28% and 43.28% [11]. - The company's revenue for the latest reporting period was approximately 111.11 million yuan, down 17.62% from the previous year, while net profit attributable to shareholders decreased by 43.28% to approximately 9.40 million yuan [12]. Group 3: Strategic Implications - The transaction is expected to leverage state-owned resources to enhance Shankai Intelligent's existing business, with Changjiang Aerospace recognized for its advantages in industrial resources and investment management [9][11]. - Changjiang Aerospace's actual controller is the State-owned Assets Supervision and Administration Commission of the People's Government of Xinzhou District, which may provide strategic support for Shankai Intelligent's future development [9].